NEW YORK – Mesothelioma patients may soon have another treatment option on the table. The Food and Drug Administration (FDA) recently granted orphan drug approval to a new vaccine that attacks cancer.
The vaccine, manufactured by Aduro Biotech, is called CRS-207. According to the manufacturer, CRS-207 is made from a version of Listeria bacteria that triggers the body to attack cells producing mesothelin, an antigen produced by many types of cancer, including mesothelioma.
“Every option a patient has right now can be extremely expensive,” Mesothelioma lawyer Ross Cellino said. “If this orphan drug trial is successful, it gives thousands of Americans another treatment option aside from surgery.”
Mesothelioma is a cancer found in a thin membrane surrounding the body’s internal organs. The cancer is most commonly caused by asbestos exposure.
In the mid-20th century, millions of Americans were exposed to asbestos fibers found in commercial and industrial products. Companies that used this insulation material often face large lawsuits for exposing workers and consumers to the product known to cause cancer.
For thousands of Americans now living with Mesothelioma, treatments have been limited to radiation, surgery, chemotherapy, or a combination. If CRS-207’s trial is successful, Aduro hopes to give patients another option to attack the cancer.
“We continue to be excited by the results from this trial of our novel immunotherapy in combination with chemotherapy in this difficult-to-treat patient population,” said Stephen T. Isaacs, chairman, president and chief executive officer of Aduro in a recent press release. “While the findings warrant further investigation, we believe CRS-207 may prove to be a very attractive therapeutic option in the armamentarium to improve overall response rates and boost the duration of those responses.”
Lawyers began drafting lawsuits for mesothelioma patients in the late 1960’s when the hazards of asbestos exposure began surfacing. Today, millions of asbestos claims have been filed in America and millions more around the globe.